August 14, 2026StocksTechnology·Bullish·fda approval

FDA clears Quantum Biopharma's Lucid-MS for mid-stage trial in progressive multiple sclerosis

The FDA cleared Lucid-MS, a drug designed to protect the nerve coating that MS destroys, for a mid-stage (Phase 2) clinical trial in progressive multiple sclerosis, issued on behalf of Quantum Biopharma ($QNTM). Quantum Biopharma's cash and digital assets more than doubled to US$9.5M from US$4.1M six months prior.

Detected & updated continuously · Source: Nebula

Story subjects

Food and Drug AdministrationQuantum Biopharma Ltd. Class B Subordinate Voting Shares Lucid Group, Inc.progressive multiple sclerosis

Sources

@blckchaindaily

🚨 QUANTUM BIOPHARMA $QNTM FDA APPROVES LUCID-$MS PIVOTAL PHASE 2 TRIAL IN PROGRESSIVE

@AGORACOM

The FDA just cleared Lucid-MS a drug designed to protect the nerve coating that MS destroys for a mid-stage clinical trial in progressive multiple sclerosis. Issued on behalf of @QuantumBP $QNTM • Cash and digital assets more than doubled to US$9.5M from US$4.1M six months https://t.co/7sLRvMVYZO